In the field of “ADC Search”, users can find ADC entries by searching ADC name, target name, antibody name, linker name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the ADCs directly related to the search term, including ADC name, Drug status, Antibody name, Linker name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “Trastuzumab deruxtecan”, find a single API entry which is named “Trastuzumab deruxtecan”;

(2) If search: “Trastuzumab”, find a series entries with ADC names;

(3) If search: “Trastuzumab deru*”, find a single entry which is named “Trastuzumab deruxtecan”;

For example, if you want to know the detail information for Trastuzumab deruxtecan, you can search “Trastuzumab deruxtecan” in the “Search for ADC” field.

Search result of the “Trastuzumab deruxtecan” shows the information of ADC ID, ADC Name, Drug Status, Representative Indication, Antibody Name, Linker Name, Payload Name and External buttons. The “ADC Info” button links to the detailed ADC information page of Trastuzumab deruxtecan. The “Antibody Info” button links to the detailed antibody information page of Trastuzumab. The “Linker Info” button links to the detailed linker information page of Mc-Gly-Gly-Phe-Gly. The “Payload Info” button links to the detailed payload information page of DXd.

In addition, users can search for ADCs by selecting the clinical status and name of the ADC in the ‘Search for ADC Entries by ADC Status’ field.Users should first select a clinical status from “Approved”, ”New Drug Application”, “Phase 3”, “Phase 2/3”, “Phase 2”, “Phase 1/2”, “Phase 1”, “Investigative”, and then search for an ADC in the list of ADCs for the selected status.

For example, if you want to know the detail information for Becotatug vedotin, which has been approved in 2025.You can select “Approved” in the ADC status column, and then select “becotatug vedotin” in the ADC name column.

Search result of the “Becotatug vedotin” shows the information of ADC ID, ADC Name, Drug Status, Representative Indication, Antibody Name, Linker Name, Payload Name and External buttons. The “ADC Info” button links to the detailed ADC information page of Becotatug vedotin. The “Antibody Info” button links to the detailed antibody information page of Becotatug. The “Linker Info” button links to the detailed linker information page of Mc-Val-Cit-PABC. The “Payload Info” button links to the detailed payload information page of MMAE.

1.1. By clicking the “ADC Info” button, the detailed information page for particular ADC will be displayed

Taking Trastuzumab deruxtecan as an example, “General Information of This Antibody Drug Conjugate (ADC)” section displays the general information of Trastuzumab deruxtecan including its ID, Name, Brand Name, Synonyms, Organization, Drug Status, Drug-to-Antibody Ratio, Structure, Targeted Antigen, Therapeutic Target and External Link(s). In addition, this section displays the general information of Trastuzumab deruxtecan including its Antibody Name, Antibody Conjugate Type, Linker Name, Payload name, Linker & Payload Combination, Absorption, Distribution, Metabolism, Toxicity and Special Approval(s).

“The indication landscape of This ADC” selection presents the highest clinical trial stage achieved by this ADC product across different oncological indications.The horizontal scroll bar at the bottom supports left-right dragging to view the full clinical stage timeline (covering Phase 1 to Approved status) and browse all cancer indication items.The vertical scroll bar on the right supports up-down dragging to scroll through the complete list of tumor indications and check the development status of each cancer type.

“The clinical trial pipeline of This ADC” selection presents the 2027 updated clinical trial pipeline of the target ADC, listing various tumor indications vertically and covering full R&D phases from Phase 1 to Approved status horizontally. The figures in cells indicate the number of clinical trials for each indication at the corresponding phase, light blue arrows show the progressive path of trials advancing to later clinical stages, and the red triangle beside breast cancer marks its approved status. Users can quickly check phase-specific trial reserves, pipeline maturity and R&D tier layout of each cancer type via rows and columns.

The “ADC-specific functional property” panel displays core functional attributes of the ADC, including Bystander Killing Effect, Binding Affinity and Circulating Stability with supporting test data and references, and allows users to click to show or hide module data.

The panel titled “General Information of The ADMET Data Related to This ADC” displays ADMET data split into four collapsible modules: Absorption, Distribution, Metabolism and Excretion. Each module lists PK indicators with specific values, units, descriptive explanations and references, and supports clicking to show or hide corresponding data details.

Some of the ADCs in the ADCdb have corresponding in vitro activity, and most are evaluated using IC50 index. The “Revealed Based on the Cell Line Data” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell line and Disease.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

Some of the drugs in the ADCdb have corresponding clinical study activity, and most are evaluated using ORR metrics. The “Identified from the Human Clinical Data” section in the “General Information of The Activity Data Related to This ADC” shows the NCT Number, Phase and Clinical Trial Description.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Administration Dosage, Enrolled Patients, Primary Endpoint and Other Endpoint.

The “Discovered Using Patient-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units and Animal Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

The “Discovered Using Cell line-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell Line and Disease Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, in vivo model and in vitro model.

1.2.By clicking the “Antibody Info” button, the detailed antibody information page will be displayed

Take Trastuzumab as an example, “General Information of This Antibody” section displays the general information of antibody, including its Name, Synonyms, Antibody Type, Antibody Subtype, Target, Heavy Chain Sequence, Light Chain Sequence and External Link(s).

Some of the antibodies in the ADCdb have corresponding binding activity, and most are evaluated using Kd and EC50 index. The “The Activity Data of This Antibody” section shows the Value, Antibody Function, and Antibody Antigen Binding Assay.

"Each Antibody Drug Conjugate Related to This Antibody" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Antibody" section systematically reveals the ADCs conjugated with this antibody. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

1.3. By clicking the “Linker Info” button, the detailed linker information page for will be displayed.

Take Mc-Val-Cit-PABC as an example, “General Information of This Linker” section displays the general information of linker, including its ID, Name, Linker Type, Antibody-Linker Relation, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

"Each Antibody Drug Conjugate Related to This Linker" section displays the ADCs associated with this linker, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Linker" section systematically reveals the ADCs conjugated with this linker. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

1.4. By clicking the “Payload Info” button, the detailed payload information page for will be displayed

Take Monomethyl auristatin E as an example, “General Information of This Payload” section displays the general information of payload, including its ID, Name, Synonyms, Target(s), MOA of Payload, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

Some of the payloads in the ADCdb have corresponding single-use activities in vitro, and most are evaluated using IC50 index. The “The Activity Data of This Payload” section shows the Standard Type, Value, Units, Cell line, Disease and Cell line ID.

"Each Antibody Drug Conjugate Related to This Payload" section displays the ADCs associated with this payload, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Payload" section systematically reveals the ADCs conjugated with this payload. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

In the field of “Antibody Search”, users can find antibody entries by searching antibody name, target name, ADC name, linker name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the antibodies directly related to the search term, including ADC name, Drug status, Antibody name, Linker name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “Mirvetuximab”, find two API entries which is named “Mirvetuximab”;

(2) If search: “Mirvetuxim*”, find a single entry which is named “Mirvetuximab”;

For example, if you want to know the detail information for Mirvetuximab, you can search “Mirvetuximab” in the “Search for Antibody” field.

Search result of the “Mirvetuximab” shows the information of Antibody ID, Antibody Name, Representative ADC Name, Linker Name, Payload Name and External buttons. The “Antibody Info” button links to the detailed antibody information page of Mirvetuximab. The “ADC Info” button links to the detailed ADC information page of Mirvetuximab soravtansine. The “Linker Info” button links to the detailed linker information page of Sulfo-SPDB. The “Payload Info” button links to the detailed payload information page of Mertansine DM4.

In addition, users can search for antibodies by selecting the clinical status and name of the antibody in the ‘Search for Antibody Entries by ADC Status’ field.Users should first select a clinical status from “Approved”, ”New Drug Application”, “Phase 3”, “Phase 2/3”, “Phase 2”, “Phase 1/2”, “Phase 1”, “Investigative”, and then search for an antibody in the list of antibodies for the selected status.

For example, if you want to know the detail information for Becotatug.You can select “Approved” in the ADC status column, and then select “Becotatug” in the antibody name column.

Search result of the “Becotatug” shows the information of Antibody ID, Antibody Name, Representative ADC Name, Linker Name, Payload Name and External buttons. The “Antibody Info” button links to the detailed antibody information page of Becotatug. The “ADC Info” button links to the detailed ADC information page of Becotatug vedotin. The “Linker Info” button links to the detailed linker information page of Mc-Val-Cit-PABC. The “Payload Info” button links to the detailed payload information page of MMAE.

2.1. By clicking the “Antibody Info” button, the detailed antibody information page will be displayed

Take Trastuzumab as an example, “General Information of This Antibody” section displays the general information of antibody, including its Name, Synonyms, Antibody Type, Antibody Subtype, Target, Heavy Chain Sequence, Light Chain Sequence and External Link(s).

Some of the antibodies in the ADCdb have corresponding binding activity, and most are evaluated using Kd and EC50 index. The “The Activity Data of This Antibody” section shows the Value, Antibody Function, and Antibody Antigen Binding Assay.

"Each Antibody Drug Conjugate Related to This Antibody" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Antibody" section systematically reveals the ADCs conjugated with this antibody. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

2.2. By clicking the “ADC Info” button, the detailed information page for particular ADCwill be displayed

Taking Brentuximab vedotin as an example, “General Information of This Antibody Drug Conjugate (ADC)” section displays the general information of Trastuzumab deruxtecan including its ID, Name, Brand Name, Synonyms, Organization, Drug Status, Drug-to-Antibody Ratio, Structure, Targeted Antigen, Therapeutic Target and External Link(s). In addition, this section displays the general information of Brentuximab vedotin including its Antibody Name, Antibody Conjugate Type, Linker Name, Payload name, Linker & Payload Combination, Absorption, Distribution, Metabolism, Toxicity and Special Approval(s).

“The indication landscape of This ADC” selection presents the highest clinical trial stage achieved by this ADC product across different oncological indications.The horizontal scroll bar at the bottom supports left-right dragging to view the full clinical stage timeline (covering Phase 1 to Approved status) and browse all cancer indication items.The vertical scroll bar on the right supports up-down dragging to scroll through the complete list of tumor indications and check the development status of each cancer type.

“The clinical trial pipeline of This ADC” selection presents the 2027 updated clinical trial pipeline of the target ADC, listing various tumor indications vertically and covering full R&D phases from Phase 1 to Approved status horizontally. The figures in cells indicate the number of clinical trials for each indication at the corresponding phase, light blue arrows show the progressive path of trials advancing to later clinical stages, and the red triangle beside breast cancer marks its approved status. Users can quickly check phase-specific trial reserves, pipeline maturity and R&D tier layout of each cancer type via rows and columns.

The “ADC-specific functional property” panel displays core functional attributes of the ADC, including Bystander Killing Effect, Binding Affinity and Circulating Stability with supporting test data and references, and allows users to click to show or hide module data.

The panel titled “General Information of The ADMET Data Related to This ADC” displays ADMET data split into four collapsible modules: Absorption, Distribution, Metabolism and Excretion. Each module lists PK indicators with specific values, units, descriptive explanations and references, and supports clicking to show or hide corresponding data details.

Some of the drugs in the ADCdb have corresponding clinical study activity, and most are evaluated using ORR metrics. The “Identified from the Human Clinical Data” section in the “General Information of The Activity Data Related to This ADC” shows the NCT Number, Phase and Clinical Trial Description.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Administration Dosage, Enrolled Patients, Primary Endpoint and Other Endpoint.

Some of the drugs in the ADCdb have corresponding in vivo pharmacokinetic activity assays, including Patient -derived Xenograft Model and Cell Line-derived Xenograft Model, most of which were evaluated using the TGI index.

The “Discovered Using Cell Line-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units and Animal Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

Some of the ADCs in the ADCdb have corresponding in vitro activity, and most are evaluated using IC50 index. The “Revealed Based on the Cell Line Data” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell line and Disease.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Method Description and In Vitro Model.

2.3. By clicking the “Linker Info” button, the detailed linker information page will be displayed.

Take Mc-Val-Cit-PABC as an example, “General Information of This Linker” section displays the general information of linker, including its ID, Name, Linker Type, Antibody-Linker Relation, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

"Each Antibody Drug Conjugate Related to This Linker" section displays the ADCs associated with this linker, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Linker" section systematically reveals the ADCs conjugated with this linker. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

2.4. By clicking the “Payload Info” button, the detailed payload information page for will be displayed.

Take Monomethyl auristatin E as an example, “General Information of This Payload” section displays the general information of payload, including its ID, Name, Synonyms, Target(s), MOA of Payload, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

Some of the payloads in the ADCdb have corresponding single-use activities in vitro, and most are evaluated using IC50 index. The “The Activity Data of This Payload” section shows the Standard Type, Value, Units, Cell line, Disease and Cell line ID.

"Each Antibody Drug Conjugate Related to This Payload" section displays the ADCs associated with this payload, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Payload" section systematically reveals the ADCs conjugated with this payload. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

In the field of “Search for Payload, users can find payload entries by searching antibody name, target name, ADC name, linker name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the payloads directly related to the search term, including ADC name, Drug status, Antibody name, Linker name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “Vobramitamab duocarmazine”, find a single entry which is named “Seco-DUBA”;

(2) If search: “Vobramita*”, find two API entries which is named ”Exatecan” and “Seco-DUBA”;

For example, if you want to know the detail information for Dxd, you can search “Dxd” in the “Search for Payload” field.

Search result of the DXd shows the information of Payload ID, Antibody Name, Representative ADC Name, Linker Name, Antibody Name and External buttons. The Payload Info” button links to the detailed payload information page of DXd. The “ADC Info” button links to the detailed ADC information page of Trastuzumab deruxtecan. The “Linker Info” button links to the detailed linker information page of Mc-Gly-Gly-Phe-Gly. The Antibody Info” button links to the detailed antibody information page of Trastuzumab.

In addition, users can search for payloads by selecting the clinical status and name of the payload in the ‘Search for Payload Entries by ADC Status’ field.Users should first select a clinical status from “Approved”, ”New Drug Application”, “Phase 3”, “Phase 2/3”, “Phase 2”, “Phase 1/2”, “Phase 1”, “Investigative”, and then search for a payload in the list of payloads for the selected status.

For example, if you want to know the detail information for DGN549.You can select “Approved” in the ADC status column, and then select “DGN549” in the payload name column.

Search result of the DGN549 shows the information of Payload ID, Antibody Name, Representative ADC Name, Linker Name, Antibody Name and External buttons. The Payload Info” button links to the detailed payload information page of DGN549. The “ADC Info” button links to the detailed ADC information page of Pivekimab sunirine. The “Linker Info” button links to the detailed linker information page of Mal-adipamide-Ala-Ala. The Antibody Info” button links to the detailed antibody information page of Pivekimab.

3.1. By clicking the “Payload Info” button, the detailed payload information page for will be displayed.

Take DXd as an example, “General Information of This Payload” section displays the general information of payload, including its ID, Name, Synonyms, Target(s), MOA of Payload, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

Some of the payloads in the ADCdb have corresponding single-use activities in vitro, and most are evaluated using IC50 index. The “The Activity Data of This Payload” section shows the Standard Type, Value, Units, Cell line, Disease and Cell line ID.

"Each Antibody Drug Conjugate Related to This Payload" section displays the ADCs associated with this payload, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Payload" section systematically reveals the ADCs conjugated with this payload. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

3.2. By clicking the “ADC Info” button, the detailed information page for particular ADCwill be displayed.

Take Trastuzumab deruxtecan as an example, “General Information of This Antibody Drug Conjugate (ADC)” section displays the general information of Trastuzumab deruxtecan including its ID, Name, Brand Name, Synonyms, Organization, Structure, Drug Status, Drug-to-Antibody Ratio, Structure. In addition, this section displays the general information of Trastuzumab deruxtecan including its Antibody Name, Antibody Conjugate Type, Linker Name, Payload name, Linker & Payload Combination, and Indication(s).

“The indication landscape of This ADC” selection presents the highest clinical trial stage achieved by this ADC product across different oncological indications.The horizontal scroll bar at the bottom supports left-right dragging to view the full clinical stage timeline (covering Phase 1 to Approved status) and browse all cancer indication items.The vertical scroll bar on the right supports up-down dragging to scroll through the complete list of tumor indications and check the development status of each cancer type.

“The clinical trial pipeline of This ADC” selection presents the 2027 updated clinical trial pipeline of the target ADC, listing various tumor indications vertically and covering full R&D phases from Phase 1 to Approved status horizontally. The figures in cells indicate the number of clinical trials for each indication at the corresponding phase, light blue arrows show the progressive path of trials advancing to later clinical stages, and the red triangle beside breast cancer marks its approved status. Users can quickly check phase-specific trial reserves, pipeline maturity and R&D tier layout of each cancer type via rows and columns.

The “ADC-specific functional property” panel displays core functional attributes of the ADC, including Bystander Killing Effect, Binding Affinity and Circulating Stability with supporting test data and references, and allows users to click to show or hide module data.

The panel titled “General Information of The ADMET Data Related to This ADC” displays ADMET data split into four collapsible modules: Absorption, Distribution, Metabolism and Excretion. Each module lists PK indicators with specific values, units, descriptive explanations and references, and supports clicking to show or hide corresponding data details.

Some of the ADCs in the ADCdb have corresponding in vitro activity, and most are evaluated using IC50 index. The “Revealed Based on the Cell Line Data” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell line and Disease.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

Some of the drugs in the ADCdb have corresponding clinical study activity, and most are evaluated using ORR metrics. The “Identified from the Human Clinical Data” section in the “General Information of The Activity Data Related to This ADC” shows the NCT Number, Phase and Clinical Trial Description.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Administration Dosage, Enrolled Patients, Primary Endpoint and Other Endpoint.

The “Discovered Using Patient-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units and Animal Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

The “Discovered Using Cell line-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell Line and Disease Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, in vivo model and in vitro model.

3.3. By clicking the “Antibody Info” button, the detailed antibody information page will be displayed

Take Trastuzumab as an example, “General Information of This Antibody” section displays the general information of antibody, including its Name, Synonyms, Antibody Type, Antibody Subtype, Target, Heavy Chain Sequence, Light Chain Sequence and External Link(s).

Some of the antibodies in the ADCdb have corresponding binding activity, and most are evaluated using Kd and EC50 index. The “The Activity Data of This Antibody” section shows the Value, Antibody Function, and Antibody Antigen Binding Assay.

"Each Antibody Drug Conjugate Related to This Antibody" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Antibody" section systematically reveals the ADCs conjugated with this antibody. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

3.4. By clicking the “Linker Info” button, the detailed linker information page will be displayed.

Take Mc-Val-Cit-PABC as an example, “General Information of This Linker” section displays the general information of linker, including its ID, Name, Linker Type, Antibody-Linker Relation, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

"Each Antibody Drug Conjugate Related to This Linker" section displays the ADCs associated with this linker, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Linker" section systematically reveals the ADCs conjugated with this linker. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

In the field of “Linker Search”, users can find linker entries by searching linker name, target name, antibody name, ADC name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the Linkers directly related to the search term, including Linker ID, Linker name, Antibody Drug Conjugate name, Antibody name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “Mc-Gly-Gly-Phe-Gly-AM”, find a single API entry which are named “Mc-Gly-Gly-Phe-Gly-AM”;

(2) If search: “Mc-Gly-Gly-Phe-Gly-A*”, find one entry which are named “Mc-Gly-Gly-Phe-Gly-AM”;

For example, if you want to know the detail information for Mc-Gly-Gly-Phe-Gly, you can search “Mc-Gly-Gly-Phe-Gly” in the “Search for Linker” field.

Search result of the “Mc-Gly-Gly-Phe-Gly” shows the information of Linker ID, Linker Name, ADC Name, Antibody Name, Payload Name and External buttons. The “Linker Info” button links to the detailed linker information page of Mc-Gly-Gly-Phe-Gly. The “ADC Info” button links to the detailed ADC information page of Ifinatamab deruxtecan. The “Antibody Info” button links to the detailed antibody information page of Ifinatamab. The “Payload Info” button links to the detailed payload information page of DX-8951 derivative (DXd).

In addition, users can search for linkers by selecting the clinical status and name of the linker in the ‘Search for Linker Entries by ADC Status’ field.Users should first select a clinical status from “Approved”, ”New Drug Application”, “Phase 3”, “Phase 2/3”, “Phase 2”, “Phase 1/2”, “Phase 1”, “Investigative”, and then search for a linker in the list of linkers for the selected status.

For example, if you want to know the detail information for Gly-Mal-Gly-Gly-Phe-Gly.You can select “Approved” in the ADC status column, and then select “Gly-Mal-Gly-Gly-Phe-Gly” in the linker name column.

Search result of the “Gly-Mal-Gly-Gly-Phe-Gly” shows the information of Linker ID, Linker Name, ADC Name, Antibody Name, Payload Name and External buttons. The “Linker Info” button links to the detailed linker information page of Gly-Mal-Gly-Gly-Phe-Gly. The “ADC Info” button links to the detailed ADC information page of Trastuzumab brengitecan. The “Antibody Info” button links to the detailed antibody information page of Trastuzumab. The “Payload Info” button links to the detailed payload information page of Ed-04.

4.1. By clicking the “Linker Info” button, the detailed linker information page for will be displayed.

Take Mc-Val-Cit-PABC as an example, “General Information of This Linker” section displays the general information of linker, including its ID, Name, Linker Type, Antibody-Linker Relation, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

"Each Antibody Drug Conjugate Related to This Linker" section displays the ADCs associated with this linker, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Linker" section systematically reveals the ADCs conjugated with this linker. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

4.2. By clicking the “ADC Info” button, the detailed linker information page will be displayed.

Take Trastuzumab deruxtecan as an example, “General Information of This Antibody Drug Conjugate (ADC)” section displays the general information of Trastuzumab deruxtecan including its ID, Name, Brand Name, Synonyms, Organization, Structure, Drug Status, Drug-to-Antibody Ratio, Structure. In addition, this section displays the general information of Trastuzumab deruxtecan including its Antibody Name, Antibody Conjugate Type, Linker Name, Payload name, Linker & Payload Combination, and Indication(s).

“The indication landscape of This ADC” selection presents the highest clinical trial stage achieved by this ADC product across different oncological indications.The horizontal scroll bar at the bottom supports left-right dragging to view the full clinical stage timeline (covering Phase 1 to Approved status) and browse all cancer indication items.The vertical scroll bar on the right supports up-down dragging to scroll through the complete list of tumor indications and check the development status of each cancer type.

“The clinical trial pipeline of This ADC” selection presents the 2027 updated clinical trial pipeline of the target ADC, listing various tumor indications vertically and covering full R&D phases from Phase 1 to Approved status horizontally. The figures in cells indicate the number of clinical trials for each indication at the corresponding phase, light blue arrows show the progressive path of trials advancing to later clinical stages, and the red triangle beside breast cancer marks its approved status. Users can quickly check phase-specific trial reserves, pipeline maturity and R&D tier layout of each cancer type via rows and columns.

The “ADC-specific functional property” panel displays core functional attributes of the ADC, including Bystander Killing Effect, Binding Affinity and Circulating Stability with supporting test data and references, and allows users to click to show or hide module data.

The panel titled “General Information of The ADMET Data Related to This ADC” displays ADMET data split into four collapsible modules: Absorption, Distribution, Metabolism and Excretion. Each module lists PK indicators with specific values, units, descriptive explanations and references, and supports clicking to show or hide corresponding data details.

Some of the ADCs in the ADCdb have corresponding in vitro activity, and most are evaluated using IC50 index. The “Revealed Based on the Cell Line Data” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell line and Disease.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

Some of the drugs in the ADCdb have corresponding clinical study activity, and most are evaluated using ORR metrics. The “Identified from the Human Clinical Data” section in the “General Information of The Activity Data Related to This ADC” shows the NCT Number, Phase and Clinical Trial Description.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Administration Dosage, Enrolled Patients, Primary Endpoint and Other Endpoint.

The “Discovered Using Patient-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units and Animal Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

The “Discovered Using Cell line-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell Line and Disease Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, in vivo model and in vitro model.

4.3. By clicking the “Antibody Info” button, the detailed antibody information page will be displayed.

Take Trastuzumab as an example, “General Information of This Antibody” section displays the general information of antibody, including its Name, Synonyms, Antibody Type, Antibody Subtype, Target, Heavy Chain Sequence, Light Chain Sequence and External Link(s).

Some of the antibodies in the ADCdb have corresponding binding activity, and most are evaluated using Kd and EC50 index. The “The Activity Data of This Antibody” section shows the Value, Antibody Function, and Antibody Antigen Binding Assay.

"Each Antibody Drug Conjugate Related to This Antibody" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Antibody" section systematically reveals the ADCs conjugated with this antibody. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

4.4. By clicking the “Payload Info” button, the detailed payload information page for will be displayed.

Take Monomethyl auristatin E as an example, “General Information of This Payload” section displays the general information of payload, including its ID, Name, Synonyms, Target(s), MOA of Payload, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

Some of the payloads in the ADCdb have corresponding single-use activities in vitro, and most are evaluated using IC50 index. The “The Activity Data of This Payload” section shows the Standard Type, Value, Units, Cell line, Disease and Cell line ID.

"Each Antibody Drug Conjugate Related to This Payload" section displays the ADCs associated with this payload, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Payload" section systematically reveals the ADCs conjugated with this payload. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

In the field of “Antigen Search”, users can find antigen entries by searching linker name, target name, antibody name, ADC name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the Antigens directly related to the search term, including Linker ID, Linker name, Antibody Drug Conjugate name, Antibody name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “ERBB2”, find a single API entry which is named “ERBB2”;

(2) If search: “ERBB*”, find a series entries with antigen names;

For example, if you want to know the detail information for ERBB2, you can search “ERBB2” in the “Antigen Search” field.

Search result of the “ERBB2” shows the information of Antigen ID, Antigen Name, ADC Name, Antibody Name, Linker name, Payload Name and External buttons. The”Antigen Info” button links to the detailed antigen information page of ”ERBB2”. The “Linker Info” button links to the detailed linker information page of SMCC. The “ADC Info” button links to the detailed ADC information page of TAA-013. The “Antibody Info” button links to the detailed antibody information page of Trastuzumab. The “Payload Info” button links to the detailed payload information page of Mertansine DM1.

In addition, users can search for antigens by selecting the clinical status and name of the antigen in the ‘Search for Linker Entries by ADC Status’ field.Users should first select a clinical status from “Approved”, ”New Drug Application”, “Phase 3”, “Phase 2/3”, “Phase 2”, “Phase 1/2”, “Phase 1”, “Investigative”, and then search for an antigen in the list of antigens for the selected status.

For example, if you want to know the detail information for CD22.You can select “Approved” in the ADC status column, and then select “B-cell receptor CD22 (CD22)” in the antigen name column.

Search result of the “B-cell receptor CD22 (CD22)” shows the information of Antigen ID, Antigen Name, ADC Name, Antibody Name, Payload Name and External buttons. The “Antigen Info” button links to the detailed linker information page of CD22. The “ADC Info” button links to the detailed ADC information page of Inotuzumab ozogamicin. The “Antibody Info” button links to the detailed antibody information page of Inotuzumab. The “Payload Info” button links to the detailed payload information page of N-acetyl-gamma-calicheamicin.

5.1. By clicking the “Antigen Info” button, the detailed linker information page for will be displayed.

Take B-cell receptor CD22 (CD22) as an example, “General Information of This Antigen” section displays the general information of CD22 including its ID, Name, Gene Name, Synonyms, Sequence, Family and Function. In addition, Uniprot Entry, HGNC ID and KEGG ID are clickable hyperlinks linking to external databases.

"Each Antibody Drug Conjugate Related to This Antigen" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The “Full List of The ADC Related to This Antigen” panel enumerates all ADCs associated with the given antigen. Entries are grouped by antibody construct, expandable via dropdown arrows. It displays ADC-specific attributes including ADC name, payload, target, linker and references. Buttons for “ADC Info” and “Antibody Info” provide quick access to detailed records.

5.2. By clicking the “ADC Info” button, the detailed linker information page will be displayed.

Take Trastuzumab deruxtecan as an example, “General Information of This Antibody Drug Conjugate (ADC)” section displays the general information of Trastuzumab deruxtecan including its ID, Name, Brand Name, Synonyms, Organization, Structure, Drug Status, Drug-to-Antibody Ratio, Structure. In addition, this section displays the general information of Trastuzumab deruxtecan including its Antibody Name, Antibody Conjugate Type, Linker Name, Payload name, Linker & Payload Combination, and Indication(s).

“The indication landscape of This ADC” selection presents the highest clinical trial stage achieved by this ADC product across different oncological indications.The horizontal scroll bar at the bottom supports left-right dragging to view the full clinical stage timeline (covering Phase 1 to Approved status) and browse all cancer indication items.The vertical scroll bar on the right supports up-down dragging to scroll through the complete list of tumor indications and check the development status of each cancer type.

“The clinical trial pipeline of This ADC” selection presents the 2027 updated clinical trial pipeline of the target ADC, listing various tumor indications vertically and covering full R&D phases from Phase 1 to Approved status horizontally. The figures in cells indicate the number of clinical trials for each indication at the corresponding phase, light blue arrows show the progressive path of trials advancing to later clinical stages, and the red triangle beside breast cancer marks its approved status. Users can quickly check phase-specific trial reserves, pipeline maturity and R&D tier layout of each cancer type via rows and columns.

The “ADC-specific functional property” panel displays core functional attributes of the ADC, including Bystander Killing Effect, Binding Affinity and Circulating Stability with supporting test data and references, and allows users to click to show or hide module data.

The panel titled “General Information of The ADMET Data Related to This ADC” displays ADMET data split into four collapsible modules: Absorption, Distribution, Metabolism and Excretion. Each module lists PK indicators with specific values, units, descriptive explanations and references, and supports clicking to show or hide corresponding data details.

Some of the ADCs in the ADCdb have corresponding in vitro activity, and most are evaluated using IC50 index. The “Revealed Based on the Cell Line Data” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell line and Disease.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

Some of the drugs in the ADCdb have corresponding clinical study activity, and most are evaluated using ORR metrics. The “Identified from the Human Clinical Data” section in the “General Information of The Activity Data Related to This ADC” shows the NCT Number, Phase and Clinical Trial Description.

Users can click on the link to jump to the full list of the corresponding Efficacy Data, Administration Dosage, Enrolled Patients, Primary Endpoint and Other Endpoint.

The “Discovered Using Patient-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units and Animal Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, and in vivo model.

The “Discovered Using Cell line-derived Xenograft Model” section in the “General Information of The Activity Data Related to This ADC” shows the Standard Type, Value, Units, Cell Line and Disease Model.

Users have the option to click on the links provided to directly access the comprehensive lists of corresponding information, including Efficacy Data, Method Description, in vivo model and in vitro model.

5.3.By clicking the “Antibody Info” button, the detailed antibody information page will be displayed.

Take Trastuzumab as an example, “General Information of This Antibody” section displays the general information of antibody, including its Name, Synonyms, Antibody Type, Antibody Subtype, Target, Heavy Chain Sequence, Light Chain Sequence and External Link(s).

Some of the antibodies in the ADCdb have corresponding binding activity, and most are evaluated using Kd and EC50 index. The “The Activity Data of This Antibody” section shows the Value, Antibody Function, and Antibody Antigen Binding Assay.

"Each Antibody Drug Conjugate Related to This Antibody" section displays the ADCs associated with this antibody, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Antibody" section systematically reveals the ADCs conjugated with this antibody. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

5.4. By clicking the “Payload Info” button, the detailed payload information page for will be displayed.

Take Monomethyl auristatin E as an example, “General Information of This Payload” section displays the general information of payload, including its ID, Name, Synonyms, Target(s), MOA of Payload, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

Some of the payloads in the ADCdb have corresponding single-use activities in vitro, and most are evaluated using IC50 index. The “The Activity Data of This Payload” section shows the Standard Type, Value, Units, Cell line, Disease and Cell line ID.

"Each Antibody Drug Conjugate Related to This Payload" section displays the ADCs associated with this payload, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Payload" section systematically reveals the ADCs conjugated with this payload. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

5.5. By clicking the “Linker Info” button, the detailed linker information page for will be displayed.

Take Mc-Val-Cit-PABC as an example, “General Information of This Linker” section displays the general information of linker, including its ID, Name, Linker Type, Antibody-Linker Relation, Structure, Formula, Isosmiles, InChI, InChIKey, IUPAC Name, Pharmaceutical Properties and External Link(s). It is important to note that Pharmaceutical Properties is calculated by RDKit.

"Each Antibody Drug Conjugate Related to This Linker" section displays the ADCs associated with this linker, with each button provided jumping to the corresponding ADC activity page.

The "Full Information of The Activity Data of The ADC(s) Related to This Linker" section systematically reveals the ADCs conjugated with this linker. The list shows the different ADCs and the stage of research. User can get an overview of the different levels of activity data for each ADC, or easily jump to the corresponding ADC activity page by clicking on ADC Info.

In the field of “Disease Search”, users can find disease entries by searching ADC name, target name, antibody name, linker name, payload name, and so on among the entire textual component of ADCdb. Query can be submitted by entering keywords into the main searching frame. The resulting webpage displays profiles of all the ADCs directly related to the search term, including ADC name, Drug status, Antibody name, Linker name, Payload name and their information links.

In order to facilitate a more customized input query, the wild characters of “*” and “?” are also supported.

(1) If search “breast cancer”, find a single API entry which is named “breast cancer”;

(2) If search: “breast”, find a single entry which is named “breast cancer”;

(3) If search: “ ICD11: 2C60-2C65”, find a single entry which is named “breast cancer”;

For example, if you want to know the detail information for breast cancer, you can search “breast cancer” in the “Disease Search” field.

Search result of the breast cancer shows the information of Disease ID, Indication Name, Indication detail name and Disease Class. The “Disease Info” button links to the detailed Disease information page of breast cancer.

In addition, users can search for diseases by selecting the disease category and disease name in the ‘Search for Disease Entries by Category Status’ field. Users should first select a disease category from “Degenerative diseases”, “Diseases of the musculoskeletal system or connective tissue”, “Certain infectious or parasitic diseases”, “Diseases of the blood or bloodforming organs”, “Diseases of the immune system”, “Endocrine, nutritional or metabolic diseases”, “Diseases of the nervous system”, “Diseases of the visual system”, “Diseases of the circulatory system”, “Diseases of the respiratory system”, “Diseases of the digestive system”, “Diseases of the skin”, “Neoplasms”, “Symptoms, signs or clinical findings, not elsewhere classified”, “Injury, poisoning or certain other consequences of external causes”, “Factors influencing health status or contact with health services”, “Coronavirus disease”, “Supplementary section for functioning assessment”, and then search for a disease in the list of diseases for the selected category.

For example, if you want to know the detail information for Bladder cancer. You can select “Neoplasms” in the disease category, and then select “Bladder cancer” in the disease name.

6.1. By clicking the “Disease Info” button, the detailed information page for particular ADC will be displayed.

Taking Metastatic breast cancer as an example, “General Information of This Disease” section displays the general information of Metastatic breast cancer, including its Disease ID, Indication Name, Indication detail name, ICD and ADC-Antigen Map of this disease.

The “General Information of The Clinical Trial Data Related to This Disease” section displays the clinical trial-relevant general information of the disease, including drug-phase distribution plot covering drugs across all clinical stages, ADC Name, and Clinical Trial Identifier. User can jump to the corresponding ADC activity page by clicking on ADC Info.